

DOCKET NO.: JJCC-0046/J & J 2032

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In Re Application of:**

**Gregory Skover**

**Confirmation No.: 5681**

**Application No.: 09/920,136**

**Group Art Unit: 3736**

**Filing Date: August 1, 2001**

**Examiner: Marmor III, Charles Alan**

**For: METHOD OF TREATING THE SKIN OF A SUBJECT**

**EXPRESS MAIL LABEL NO: EL 999285362 US**  
**DATE OF DEPOSIT: August 17, 2004**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

**INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

- ☐ In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or

before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

☐ In accordance with § 1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

☐ Certification in Accordance with § 1.97(e) is attached; or

☐ The fee of \$180.00 as set forth in § 1.17(p) is attached.

☒ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

☐ Certification in Accordance with § 1.97(e) is attached;  
or

☒ The fee of \$180.00 as set forth in § 1.17(p) is attached.

☐ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of \$180.00 as set forth in § 1.17(p).

- ☒ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.
- ☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith
- ☐ Copies of references listed on the attached Form PTO 1449 are not required to be submitted pursuant to the June 30, 2003 recent revisions to 37 CFR § 1.98(a)(2)(i).

EXCEPT THAT:


- ☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
- ☐ In accordance with § 1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application:
- ☐ Copies of references [list as appropriate] listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior Application No.

, filed .

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

There are no listed references which are not in the English language.

Date: August 17, 2004

  
Wendy A. Choi  
Registration No. 36,697

WOODCOCK WASHBURN LLP  
One Liberty Place - 46th Floor  
Philadelphia, PA 19103  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439



<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>JJCC-0046/J &amp; J 2032</b>	Application No. <b>09/920,136</b>
		Applicant <b>Gregory Skover</b>	
		Filing Date <b>August 1, 2001</b>	Group <b>3736</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	1	Badcock, N.R. et al., "The Pharmacokinetics of Ketoconazole after Chronic Administration in Adults", <i>Eur J. Clin Pharmacol</i> , <b>1987</b> , 33, 531-534	
	2	Bork, K. et al., "Histamine Levels in Interstitial Fluid of Lesional and Perilesional Skin in Patients with Chronic Idiopathic Urticaria", <i>Arch Dermatol Res.</i> , <b>1979</b> , 266, 269-276	
	3	Svedman, P. "Skin Mini-Erosion Sampling Technique: Feasibility Study with Regard to Serial Glucose Measurement", <i>Pharmaceutical Research</i> , <b>1988</b> , 15(6), 883-888	
	4	Gabor, "Sensors in Biomedical Applications", <i>Technomic Pub Co.</i> , <b>2000</b> , 223-306	
	5	Henry, et al., "Microfabricated Microneedles: A Novel Approach to Transdermal Drug Delivery", <i>Journal of Pharmaceutical Sciences</i> , 1988, 87(8), 922-925	
	6	International Cosmetic Ingredient Dictionary and Handbook, <b>1997</b> , 7 <sup>th</sup> Edition(2), 1650-1667, 1626	
	7	Krogstad, A.L. et al., "Microdialysis methodology for the measurement of dermal interstitial fluid in humans" <i>British Journal of Dermatology</i> , <b>1996</b> , 134(6), 1005-1012	
	8	"Laboratory Procedures Used by the Clinical Chemistry Division, Centers for Disease Control, for the Second Health and Nutrition Examination Survey" ( <i>Hanes II</i> ) 1976-1980, USDHS, Public Health Services, IV., Analytical Methods, Vitamin C, Atlanta, Ga., 17-20, 69	
	9	Liron, et al., "Novel Approaches in Biosensors and Rapid Diagnostic Assays", <i>Plenum Pub Corp.</i> , <b>2000</b>	
	10	Maile, L.A. et al., "Active and Inhibitory Components of the Insulin-Like Growth Factor Binding Protein-3 Protease System in Adult Serum, Interstitial, and Synovial Fluid", <i>Endocrinology</i> , <b>1998</b> , 139(12), 4772-4781, XP-002230077	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

PTO-1449 has received and is being  
 processed by the Patent and Trademark Office



<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>JJCC-0046/J &amp; J 2032</b>	Application No. <b>09/920,136</b>
		Applicant <b>Gregory Skover</b>	
		Filing Date <b>August 1, 2001</b>	Group <b>3736</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>11</b>	Service, F.J. et al., "Dermal Interstitial Glucose as an Indicator of Ambient Glycemia", <i>Diabetes Care</i> , <b>1997</b> , 20(9),1426-1429	
	<b>12</b>	Svedman, P. et al., "Skin Mini-Erosion Sampling Technique: Feasibility Study with Regard to Serial Glucose Measurement", <i>Pharmaceutical Research</i> , <b>1998</b> , 15(6), 883-888	
	<b>13</b>	Tope, W.D., "Multi-Electrode Radio Frequency Resurfacing of Ex Vivo Human Skin", <i>Dermatol Surg</i> , <b>1999</b> , 25, 348-352	
	<b>14</b>	"Laboratory Procedures used by the Clinical Chemistry Division, Centers for Disease Control, for the Second health and Nutrition Examination Survey (HANESII), U.S. Dept of Health and Human Services, Public Health Services, Atlanta. Georgia, <b>1979</b> , 17-19, 69	
	<b>15</b>	Vaillant, L. et al., "Erythromycin Ethyl Succinate: Diffusion through Interstitial Dermal Fluid", <i>Eur J Clin Pharmacol</i> , <b>1987</b> , 33(5), 529-530	
	<b>16</b>	Zimmerli, W. et al., "Pharmacokinetics of Cefetamet in Plasma and Skin Blister Fluid", <i>Antimicrobial Agents and Chemotherapy</i> , <b>1996</b> , 40(1), 102-104	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	